AUPH News and Press, Aurinia Pharmaceuticals Inc From 11/06/21

Bristol Myers Squibb (NYSE: BMY) is reportedly interested in acquiring Aurina Pharmaceuticals (NASDAQ: AUPH) . In this Motley Fool Live video recorded on Oct. 27 , Fool contributors Keith Speights and Brian Orelli discuss whether this deal would be a smart move ...

Image source: The Motley Fool. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Q3 2021 Earnings Call Nov 3, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Aurinia Pharmaceuticals Inc (AUPH) Q3 2021 Earnings Call Transcr...

Aurinia Pharmaceuticals Inc. (AUPH) Q3 2021 Earnings Conference Call November 03, 2021 8:30 AM ET Company Participants Dana Lynch – Investor Relations and Corporate Communications Peter Greenleaf – President and Chief Executive Officer Joe Miller – Chief Financial Officer...

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) traded at a new 52-week high today of $33.94. Approximately 1.2 million shares have changed hands today, as compared to an average 30-day volume of 4.5 million shares. Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides produc...

On Oct. 22, Bloomberg News reported that Bristol Myers Squibb (NYSE: BMY) was considering a takeover bid for the autoimmune drugmaker Aurinia Pharmaceuticals (NASDAQ: AUPH) . Since then, additional rumors have surfaced that other pharma giants such as GlaxoSmithKline ...

Aurinia Pharmaceuticals (NASDAQ:AUPH) has lost ~5.3% in the pre-market after reporting a mixed financial performance for Q3 2021. While the company beat the consensus as revenue at $14.7M showed a sequential improvement of ~122%, the earnings lagged expectations. Following the ...

Aurinia Pharma (NASDAQ:AUPH): Q3 GAAP EPS of -$0.39 misses by $0.06. Revenue of $14.66M beats by $0.51M. Shares +1.56% PM. Press Release Gross margin for the three and nine months ended September 30, 2021 was approximately 98% and 97% respectively. “We are very pleased with Q3 res...

$14.7 million in net revenue for the third quarter 2021 (122% increase from second quarter 2021) Steady increases in LUPKYNIS Patient Start Forms, Conversion Rates and Payer Coverage Addition of two preclinical assets with potential in rare autoimmune conditions to gro...

Aurinia Pharma (NASDAQ:AUPH) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is -$0.33 and the consensus Revenue Estimate is $14.15M. Aurinia shares rose 14% in reaction to posting financial results for Q2 ended June...

AAWW, ACLS, ACRE, AGIO, AMRN, AMRX, ATH, ATY, AUPH, AUTL, AVA, BCRX, BDC, BDSI, BGCP, BIP, OTCPK:BMWYY, BR, BRSP, BWA, CDW, CIM, CIO, CLH, CLVS, CPRI, CRL, CRTO, CSTE, CTRA, CVE, CVS, CWH, DFIN, DISCA, OTCQX:DLAKF, OTCPK:DNNGY, DNOW, EAT, EMR, ES, ETR, EVRG, EVRI, EXC, EXPI, EYPT, FDP, FUN, F...